林 丈晴

Hayashi Takeharu

  • 教授
  • 学位:博士(医学)

基本情報

所属

  • Undergraduate School of Medicine / Faculty of Medicine
  • Graduate School of Medicine / Course of Advanced Medical Science
  • Graduate School of Medicine / Course of Medical Science

詳細情報

研究キーワード

  • Genome-based drug discovery
  • disease-causing gene
  • Cardiomyopathy

研究分野

  • Life sciences Cardiology
  • Life sciences Internal medicine - General
  • Life sciences Medical biochemistry
  • Life sciences Pharmacology
  • Life sciences Clinical pharmacy
  • Life sciences Physiology
  • Life sciences Anatomy

論文

Clinical characteristics of female Fabry disease patients with hypertrophic cardiomyopathy with mid-ventricular obstruction.

Pediatric hypertrophic cardiomyopathy caused by a novel TNNI3 variant

Pathogenic variant of RBM20 in a multiplex family with hypertrophic cardiomyopathy

A Novel Titin Truncation Variant Linked to Familial Dilated Cardiomyopathy Found in a Japanese Family and Its Functional Analysis in Genome-Edited Model Cells

Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.

Phosphorylation of the RSRSP stretch is critical for splicing regulation by RNA-Binding Motif Protein 20 (RBM20) through nuclear localization

Clinical and genetic backgrounds of hypertrophic cardiomyopathy with mid-ventricular obstruction.

Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy

Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance.

Barth syndrome associated with triple mutation

Phenotypic expression of a novel desmin gene mutation: hypertrophic cardiomyopathy followed by systemic myopathy.

Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body

Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: identification of a MYH7 mutation and MYBPC3 mutations

Current status of the genetic analysis for HCM and the various causes

A patient with alcoholic cardiomyopathy, who was interrupted dental treatment because of tachycardic atrial fibrillation with ventricular aberration - A case report

A patient with alcoholic cardiomyopathy, who was interrupted dental treatment because of tachycardic atrial fibrillation with ventricular aberration - A case report

Delta-Sarcoglycan Gene Therapy Halts Progression of Cardiac Dysfunction, Improves Respiratory Failure, and Prolongs Life in Myopathic Hamsters

Bilateral Rectus Sheath Hematoma Developing During Anticoagulant Therapy

Impaired binding of ZASP/Cypher with phosphoglucomutase 1 is associated with dilated cardiomyopathy

Three-dimensional electron microscopy reveals new details of membrane systems for Ca2+ signaling in the heart

共同研究?競争的資金等の研究課題

Elucidation of pathogenesis in high-risk group hypertrophy cardiomyopathy

Towards the provision of novel therapies for cardiomyopathy

心筋症の遺伝的病因に基づく新規予防、治療法の開発

新規原因遺伝子を基盤とした心筋症の治療法の開発

遺伝性心筋症の病因と病態形成機構の解明を基盤とした心不全治療、予防戦略の開発

心筋症の発症原因にもとづく個別化予防、治療法の開発

特発性心筋症の病態解明に基づく治療法の開発

ResearchMapへ移動します

Contact Us

Inquiries about coverage

Public Affairs Division Public Affairs and Communications Department

Tel. 0463-63-4670(direct dialing)